GEMCITABINE , JNJ-17000139, MITOMYCIN
17000139BLC3004
Phase 3 small_molecule active
Quick answer
GEMCITABINE , JNJ-17000139, MITOMYCIN for High-Risk Non-muscle-invasive Bladder Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- High-Risk Non-muscle-invasive Bladder Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active